Sublingual and buccal film compositions
DC CAFCFirst Claim
Patent Images
1. A film dosage composition comprising:
- a. A polymeric carrier matrix;
b. A therapeutically effective amount of buprenorphine or a pharmaceutically acceptable salt thereof;
c. A therapeutically effective amount of naloxone or a pharmaceutically acceptable salt thereof; and
d. A buffer in an amount to provide a local pH for said composition of a value sufficient to optimize absorption of said buprenorphine, wherein said local pH is from about 3 to about 3.5 in the presence of saliva.
10 Assignments
Litigations
4 Petitions
Accused Products
Abstract
The present invention relates to products and methods for treatment of narcotic dependence in a user. The invention more particularly relates to self-supporting dosage forms which provide an active agent for treating narcotic dependence while providing sufficient buccal adhesion of the dosage form.
195 Citations
19 Claims
-
1. A film dosage composition comprising:
-
a. A polymeric carrier matrix; b. A therapeutically effective amount of buprenorphine or a pharmaceutically acceptable salt thereof; c. A therapeutically effective amount of naloxone or a pharmaceutically acceptable salt thereof; and d. A buffer in an amount to provide a local pH for said composition of a value sufficient to optimize absorption of said buprenorphine, wherein said local pH is from about 3 to about 3.5 in the presence of saliva. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
-
-
9. A method of treating narcotic dependence of a user, comprising the steps of:
-
a. providing a composition comprising; i. A polymeric carrier matrix; ii. A therapeutically effective amount of buprenorphine or a pharmaceutically acceptable salt thereof; iii. A therapeutically effective amount of naloxone or a pharmaceutically acceptable salt thereof; and iv. A buffer in an amount to provide a local pH of about 3 to about 3.5 for said composition of a value sufficient to optimize absorption of said buprenorphine and also sufficient to inhibit absorption of said naloxone; and b. administering said composition to the oral cavity of a user. - View Dependent Claims (10, 11, 12, 13, 14)
-
- 15. An orally dissolving film formulation comprising buprenorphine and naloxone, wherein said formulation provides an in vivo plasma profile having a Cmax of between about 0.624 ng/ml and about 5.638 ng/ml for buprenorphine and an in vivo plasma profile having a Cmax of between about 41.04 pg/ml to about 323.75 pg/ml for naloxone.
Specification